Eagle Pharmaceuticals Announces Commercial Availability of Docetaxel Injection, Non-Alcohol Formula

WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–Eagle Pharmaceuticals (“Eagle” or the “Company”) (NASDAQ:EGRX) today announced the shipment and commercial availability of Alcohol-Free Docetaxel Injection (“Docetaxel Injection”). Docetaxel Injection is approved for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.